Patients with atopic dermatitis had an increased risk for COVID-19 infection despite age and sex, and some comorbidities were linked to a greater risk.

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

The poster presentations will be available on Connect’s website under the Presentations and Publications section.

Real-world data from Australian patients show that upadacitinib demonstrates strong efficacy in treating atopic dermatitis, ...

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, discusses the value of the win ratio approach in ...

Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their disease, according to a poster at the American Thoracic Society International ...

The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

A new study published in the Journal of the European Academy of Dermatology and Venerology found dupilumab to have a ...

FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial shows significant symptom reduction ...

The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...